Filing Analysis
Citius Oncology, Inc. filed an 8-K to announce its results of operations for the third quarter of fiscal 2026. The filing serves as a formal announcement of the press release containing these financial results.
📋 Key Facts
- Report date: August 14, 2026
- Subject matter: Results of operations for the third quarter of fiscal 2026
- The company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933.
- Exhibit 99.1 contains the full press release regarding financial results.
Citius Oncology, Inc. announced the expansion of its Board of Directors through the appointment of Jonathan Peri, Ph.D., J.D., effective August 10, 2026. Dr. Peri joins as an independent director and will serve until the 2028 annual meeting.
📋 Key Facts
- Board expanded to nine individuals.
- Jonathan Peri, Ph.D., J.D. appointed as a Class I member of the Board effective August 10, 2026.
- Dr. Peri is designated as an independent director under SEC and Nasdaq rules.
- The Board remains majority independent following this appointment.
- Dr. Peri brings extensive leadership experience, including serving as President of Manor College since 2015.
Citius Oncology, Inc. issued an 8-K to announce a press release regarding the expanding base of institutional accounts ordering its product, LYMPHIR®.
📋 Key Facts
- Filed on August 5, 2026.
- The company announced an update concerning increased institutional adoption/ordering of LYMPHIR®.
- The filing is categorized under Item 8.01 (Other Events) to furnish a press release.
Citius Oncology, Inc. filed an 8-K to report the presentation of clinical data at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 1, 2026.
📋 Key Facts
- The company issued a press release on June 1, 2026, regarding clinical data presentations.
- The data was presented at the Annual Meeting of the American Society of Clinical Oncology.
- The press release is attached as Exhibit 99.1.
Citius Oncology, Inc. announced its financial results for the second quarter of fiscal 2026. The results were released via a press release on May 15, 2026, and furnished to the SEC under Item 2.02.
📋 Key Facts
- The filing reports results of operations for the second quarter of fiscal 2026.
- The report was filed on May 15, 2026, which was also the date of the earliest event reported.
- The company is an emerging growth company as defined in Rule 405 of the Securities Act.
- The common stock is traded on The Nasdaq Capital Market under the symbol CTOR.
Citius Oncology (CTOR) executed a major financing package including an $11.5 million warrant inducement transaction and a $25 million tiered loan facility. The financing is intended to fund the commercialization of LYMPHIR, but involves significant dilution through the issuance of 25.5 million new warrants and a related-party debt conversion feature.
🚩 Red Flags
- Significant dilution: 25.5 million new warrants issued plus 12.7 million shares from induced exercise.
- High-cost debt: The loan facility has a 12.75% interest floor and a $1,062,500 final payment fee.
- Related-party transaction: Amendment of the $3.8M promissory note with the Parent company to include a conversion feature at $0.90.
- Milestone-dependent funding: Tranches 2 and 3 ($15M total) are contingent on net revenue and liquidity milestones.
- Variable Rate Transaction restriction: One-year prohibition on certain future financings suggests restrictive debt covenants.
📋 Key Facts
- Entered a Warrant Inducement Agreement on May 5, 2026, to exercise 12,777,778 existing warrants at a reduced price of $0.90 per share.
- Issued 25,555,556 new warrants at an exercise price of $0.90 as an inducement, representing a 2-for-1 issuance ratio.
- Secured a $25 million Loan and Security Agreement with Avenue Venture Opportunities Fund II, with $10 million funded immediately (Tranche 1).
- Loan interest is the greater of (6.00% + Prime) or 12.75%, secured by all company assets including intellectual property.
- Amended a $3.8 million promissory note with Parent company (Citius Pharmaceuticals) to allow conversion into common stock at $0.90 per share and extend maturity.
- H.C. Wainwright acted as placement agent, receiving a 7% cash fee and warrants for 894,444 shares.
Citius Oncology, Inc. announced the initial shipment of its oncology product LYMPHIR™ (denileukin diftitox-cxdl) to Europe. This shipment marks a key commercial milestone as the company begins international distribution through a regional partner.
📋 Key Facts
- On April 29, 2026, the company issued a press release regarding the first shipment of LYMPHIR™ to Europe.
- The distribution is being handled through an unnamed regional distribution partner.
- The product involved is LYMPHIR™ (denileukin diftitox-cxdl), an oncology therapeutic.
- The filing was made under Item 8.01 (Other Events).
Citius Oncology, Inc. received a deficiency notice from Nasdaq on April 22, 2026, because its common stock bid price closed below $1.00 for 30 consecutive business days. The company has until October 19, 2026, to regain compliance with the minimum bid price requirement.
🚩 Red Flags
- Stock price has fallen into penny stock territory (below $1.00).
- The company explicitly mentions a reverse stock split as a potential necessity to cure the deficiency.
- Risk of delisting from the Nasdaq Capital Market if compliance is not achieved by the deadline.
📋 Key Facts
- Nasdaq notification received on April 22, 2026, regarding non-compliance with Listing Rule 5550(a)(2).
- Common stock bid price was below $1.00 for 30 consecutive business days.
- The company has a 180-day compliance period ending October 19, 2026.
- Compliance requires the bid price to close at $1.00 or more for at least 10 consecutive business days.
- A second 180-day extension may be available if the company meets other listing standards and considers a reverse stock split.
Citius Oncology, Inc. issued a press release on March 31, 2026, providing a commercial update on the U.S. launch of its oncology product, LYMPHIR™ (denileukin diftitox-cxdl).
📋 Key Facts
- The filing was made under Item 8.01 (Other Events) on March 31, 2026.
- The update concerns the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl) in the United States.
- The company is an emerging growth company as defined by the Securities Act.
- The full details of the commercial update are contained in Exhibit 99.1.
Citius Oncology announced positive topline results from an investigator-initiated Phase 1 clinical trial evaluating LYMPHIR™ in combination with pembrolizumab (KEYTRUDA®). The study targeted patients with recurrent or refractory gynecologic cancers, specifically focusing on T-regulatory cell depletion.
📋 Key Facts
- The Phase 1 trial was conducted by investigators at the University of Pittsburgh.
- The study evaluated LYMPHIR™ (denileukin diftitox-cxdl) in combination with pembrolizumab.
- Target indications included recurrent or refractory ovarian and endometrial malignancies.
- Results indicated positive direct T-regulatory (Treg) cell depletion activity.
- The announcement was made via press release on March 10, 2026.
Citius Oncology announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial of LYMPHIR™ (denileukin diftitox cxdl). The trial evaluated the drug's performance when administered prior to commercial CD19 directed CAR T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
📋 Key Facts
- Reported positive topline results from a Phase 1 trial on March 4, 2026.
- The trial evaluated LYMPHIR™ (E7777) as a pre-treatment for commercial CD19 CAR T therapy.
- Targeted patient population was high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- The study was an investigator-initiated trial focused on safety and efficacy.
Citius Oncology, Inc. filed an 8-K to furnish its press release announcing the results of operations for the first quarter of fiscal 2026.
📋 Key Facts
- The filing is a standard announcement of Q1 2026 financial results via press release (Exhibit 99.1).
- Report date: February 13, 2026.
- The company is an emerging growth company.
Citius Oncology, Inc. issued an 8-K to furnish a press release announcing its full-year fiscal 2025 results of operations. This is a routine earnings announcement filing.
📋 Key Facts
- Report date: December 23, 2025
- The company announced full year fiscal 2025 results via press release (Exhibit 99.1)
- Company is an emerging growth company as defined by the SEC.
Citius Oncology, Inc. closed a combined registered direct offering and private placement (PIPE) on December 10, 2025, raising approximately $18 million in gross proceeds. The financing includes significant issuance of warrants and pre-funded warrants to an institutional investor.
🚩 Red Flags
- Significant potential dilution: Issuance of over 15 million pre-funded warrants and millions of common/placement agent warrants.
- Complex warrant structures: Pre-funded warrants at near-zero exercise prices ($0.0001) create massive immediate dilution upon exercise.
- Related party debt restructuring: Amendment to a promissory note with Citius Pharmaceuticals, Inc. (likely an affiliate or related entity).
- Warrant overhang: Placement agent received 1,155,963 warrants; existing investor warrants were also amended/reduced in price.
📋 Key Facts
- Total aggregate gross proceeds: ~$18.0 million; Net proceeds: ~$15.2 million.
- Registered direct offering: 1,284,404 shares at $1.09 per share.
- PIPE placement: Up to 15,229,358 pre-funded warrants and 15,229,358 common warrants.
- Pre-funded warrants have an exercise price of $0.0001 per share.
- H.C. Wainwright and Co., LLC acted as exclusive placement agent with a 7.0% cash fee.
- The company amended a promissory note due to Citius Pharmaceuticals, Inc., tying maturity to the closing of at least $50 million in total capital raises.
- Existing warrants from July and September 2025 were amended to reduce exercise price to $1.09.
Citius Oncology, Inc. announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl), an FDA-approved treatment for relapsed or refractory Stage I–III cutaneous T-cell lymphoma. The company also updated its corporate presentation.
📋 Key Facts
- Commercial launch of LYMPHIR™ (denileukin diftitox-cxdl) announced on December 1, 2025.
- LYMPHIR™ is an IL-2 receptor-directed fusion protein approved by the FDA.
- Indication: Treatment of adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.
- Company updated its Corporate Presentation (Exhibit 99.1).
Citius Oncology, Inc. held its 2025 annual meeting of stockholders where shareholders approved an amendment to the 2024 Omnibus Stock Incentive Plan and ratified Wolf & Company, P.C. as independent auditors.
📋 Key Facts
- Stockholders approved increasing authorized shares under the 2024 Omnibus Stock Incentive Plan from 15,000,000 to 30,000,000.
- Myron Holubiak and Joel Mayersohn were elected as Class I directors for three-year terms expiring in 2028.
- Wolf & Company, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending September 30, 2025.
Citius Oncology, Inc. filed an 8-K to provide an updated Corporate Presentation via its website as of October 23, 2025.
📋 Key Facts
- The company released an updated Corporate Presentation on October 23, 2025.
- The presentation is attached as Exhibit 99.1 and incorporated by reference.
- The filing was made pursuant to Item 7.01 (Regulation FD Disclosure).
Citius Oncology, Inc. issued warrants to a financial advisor and approved a significant expansion of its 2024 Omnibus Stock Incentive Plan.
🚩 Red Flags
- Significant dilution potential due to doubling the authorized share pool for stock incentives (from 15M to 30M shares).
- Issuance of warrants to a financial advisor suggests potential compensation-related equity issuance.
📋 Key Facts
- Issued warrants to a financial advisor for up to 360,000 shares of common stock on September 19, 2025.
- Warrant exercise price is set at $2.1875 per share.
- Warrants are exercisable starting March 10, 2026, and expire on March 10, 2031.
- The Board approved an amendment to the 2024 Omnibus Stock Incentive Plan to increase reserved shares from 15,000,000 to 30,000,000.
Citius Oncology, Inc. completed a registered direct offering of 5,142,858 shares and a private placement of warrants for $7.48 million in net proceeds. The filing also includes an amendment to a promissory note with Citius Pharmaceuticals, linking its maturity to future capital raises totaling $30 million.
🚩 Red Flags
- Significant dilution: The offering of 5.1M shares and associated warrants represents a substantial increase in share count.
- Warrant overhang: Issuance of both investor warrants and placement agent warrants creates future dilutive pressure.
- Debt maturity contingency: The amendment to the promissory note indicates the company is under significant liquidity pressure, as repayment is contingent upon raising an additional $30 million.
📋 Key Facts
- Completed a 'best-efforts' registered direct offering of 5,142,858 shares at a combined unit price of $1.75 (including warrants).
- Estimated net proceeds from the offering are approximately $7.48 million.
- Issued warrants to investors with an exercise price of $1.84 per share, exercisable in six months and expiring in 5.5 years.
- Paid Maxim Group LLC a 7.0% cash fee plus reimbursement of expenses up to $100,000, plus warrants equal to 4.0% of shares sold.
- Amended a promissory note with Citius Pharmaceuticals; maturity is now tied to the company closing at least $30 million in aggregate gross proceeds via debt, equity, or royalty-backed monetization.
Citius Oncology, Inc. filed an 8-K to report the filing of a prospectus supplement related to a public offering of common stock and warrants. The filing is intended to update its Form S-1 registration statement following the recent quarterly report.
🚩 Red Flags
- Public offering involving warrants often leads to potential dilution for existing shareholders.
📋 Key Facts
- Filed a prospectus supplement to its Form S-1 registration statement on August 18, 2025.
- The Form S-1 was declared effective on July 15, 2025.
- A public offering of common stock and warrants occurred on July 17, 2025.
- The update is required because the company's recent 10-Q cannot yet be incorporated by reference into the S-1.
Citius Oncology, Inc. filed an 8-K to furnish its third quarter fiscal 2025 results of operations via a press release. The filing is a standard earnings announcement and does not contain material changes to corporate structure or financial health in the text provided.
📋 Key Facts
- The company issued a press release on August 12, 2025, regarding Q3 fiscal 2025 results of operations.
- The filing is made pursuant to Item 2.02 (Results of Operations and Financial Condition).
- The report was signed by Leonard Mazur, Chairman and CEO.
Citius Oncology, Inc. completed a 'best-efforts' public offering of 6,818,182 units consisting of one share and one warrant per unit at $1.32 per unit. The offering is expected to net approximately $7.44 million in proceeds for the company.
🚩 Red Flags
- Significant dilution: The issuance of over 6.8 million new shares and corresponding warrants will result in substantial dilution for existing shareholders.
- Warrant overhang: The issuance of nearly equal numbers of warrants to the public and the placement agent creates significant future dilution potential.
📋 Key Facts
- Offered 6,818,182 shares of common stock and 6,818,182 warrants at a combined price of $1.32 per unit.
- Warrants have an exercise price of $1.32 and expire in five years.
- Estimated net proceeds are approximately $7.44 million after fees and expenses.
- Placement Agent (Maxim Group LLC) received a 7.0% cash fee plus reimbursement for expenses up to $125,000.
- The company issued warrants to the Placement Agent equal to 4.0% of the shares sold in the offering, with an exercise price of $1.65.
- The offering was conducted under a previously declared effective S-1 registration statement.
Citius Oncology, Inc. has regained compliance with Nasdaq's minimum bid price requirement after meeting the 12-consecutive-trading-day threshold.
🚩 Red Flags
- The company was previously in danger of delisting due to a low stock price (below $1.00).
📋 Key Facts
- The Company received written notice from Nasdaq on June 26, 2025, confirming compliance with Listing Rule 5550(a)(2).
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater for 12 consecutive trading days (June 6, 2025 - June 24, 2025).
- Nasdaq has officially considered the compliance matter closed.
Citius Oncology, Inc. announced that preparations for the commercial launch of its FDA-approved immunotherapy, LYMPHIR™, are nearing completion.
📋 Key Facts
- Announcement date: June 17, 2025.
- Product name: LYMPHIR™.
- Indication: Treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
- Status: FDA-approved immunotherapy nearing commercial launch.
Citius Oncology, Inc. filed an 8-K to announce the release of its second quarter fiscal 2025 results of operations via a press release.
📋 Key Facts
- Report date: May 14, 2025
- The filing relates to Item 2.02 (Results of Operations and Financial Condition)
- A press release dated May 14, 2025, was furnished as Exhibit 99.1
- Company is an emerging growth company
Citius Oncology, Inc. received a notification from Nasdaq stating the company's common stock has failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until October 20, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price ($1.00)
- Potential requirement for a reverse stock split to regain compliance
📋 Key Facts
- Nasdaq notified the company on April 23, 2025, regarding a violation of Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule).
- The stock has closed below $1.00 for the last 30 consecutive business days.
- A compliance period is granted until October 20, 2025.
- To regain compliance during a potential second 180-day window, the company may need to effect a reverse stock split.
Citius Oncology has entered into a letter agreement with Eisai Co., Ltd. to restructure the payment schedule for significant milestone and development costs related to LYMPHIR (denileukin diftitox). The company is restructuring approximately $14 million in obligations into a series of payments through December 2025.
🚩 Red Flags
- Restructuring of significant debt/obligations suggests liquidity constraints or cash flow management issues.
- The company is deferring millions in payments over the next 9 months, indicating a need to preserve immediate cash.
- Potential for future default if revenue from LYMPHIR does not materialize as expected by July 2025.
📋 Key Facts
- Citius Oncology entered into a letter agreement with Eisai on March 28, 2025, to amend the License Agreement for LYMPHIR.
- The restructuring covers an aggregate obligation including a $5.9M milestone payment and ~$8.23M in development/inventory costs.
- Payment schedule: $2,535,317.77 due by July 15, 2025; followed by four monthly payments of $2,350,000 each; with a final payment of $2,197,892.07 on or before December 15, 2025.
- All restructured payments accrue interest at a rate of 2% per annum from the original due date.
- The parties released each other from claims related to previous failures to pay these specific obligations.
Citius Oncology, Inc. filed an 8-K to announce the release of its operating results for the first quarter of fiscal 2025.
📋 Key Facts
- The filing was made on February 14, 2025.
- The company issued a press release (Exhibit 99.1) regarding Q1 fiscal 2025 results of operations.
- The report is filed under Item 8.01 (Other Events).
Citius Oncology, Inc. announced that its product LYMPHIR™ (denileukin diftitox-cxdl) has been assigned a permanent J-code by CMS. This regulatory milestone facilitates easier reimbursement and administration in clinical settings.
📋 Key Facts
- LYMPHIR™ (denileukin diftitox-cxdl) received a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code from CMS.
- The announcement was made via press release on February 6, 2025.
- The filing is an Item 8.01 'Other Events' disclosure.
Citius Oncology, Inc. issued a press release regarding progress in preparing for the commercial launch of its immunotherapy product, LYMPHIR™, intended for treating cutaneous T-cell lymphoma (CTCL). The filing serves as a formal announcement of clinical/commercial milestone progress.
📋 Key Facts
- Announcement date: January 7, 2025
- Product name: LYMPHIR™
- Indication: Relapsed or refractory cutaneous T-cell lymphoma (CTCL) in adults
- Nature of event: Progress in preparations for commercial launch
Citius Oncology, Inc. has retained Jefferies LLC as an exclusive financial advisor to evaluate strategic alternatives intended to maximize shareholder value.
🚩 Red Flags
- Strategic alternative evaluations often precede significant corporate restructuring, such as a sale of the company, merger, or liquidation.
📋 Key Facts
- Date of event: January 6, 2025
- Financial Advisor: Jefferies LLC (exclusive)
- Objective: Evaluating strategic alternatives to maximize shareholder value
- Company Status: Emerging growth company
Citius Oncology, Inc. filed an 8-K to furnish its full year fiscal 2024 results of operations via a press release. This is a routine earnings announcement filing.
📋 Key Facts
- The company issued a press release on December 27, 2024, announcing full year fiscal 2024 results.
- The filing includes Exhibit 99.1 containing the press release details.
Citius Oncology, Inc. announced preliminary results from an ongoing investigator-initiated Phase I clinical trial regarding a combined regimen of pembrolizumab and LYMPHIR™ for patients with recurrent solid tumors.
📋 Key Facts
- Preliminary results released on November 11, 2024.
- Trial is an investigator-initiated Phase I study.
- Regimen evaluates the combination of pembrolizumab and LYMPHIR™ (denileukin diftitox-cxdl or E7777).
- Target population: patients with recurrent solid tumors.
Citius Oncology, Inc. announced a partial deferral of a milestone payment due from Dr. Reddy’s Laboratories SA. The payment was triggered by the FDA approval of LYMPHIR™ and was originally scheduled for September 9, 2024.
🚩 Red Flags
- Deferral of cash inflows (milestone payments) can indicate liquidity management issues or friction with major partners.
- The deferral is 'partial,' meaning the company did not receive the full amount expected on the scheduled date.
📋 Key Facts
- The milestone payment was triggered by the regulatory approval of LYMPHIR™ by the U.S. FDA.
- The original due date for the payment was September 9, 2024.
- Dr. Reddy’s Laboratories SA agreed to a partial deferral of this milestone payment without penalty.
- All other terms of the Asset Purchase Agreement dated September 1, 2021, remain in effect.
Citius Oncology, Inc. issued an 8-K to announce that its product LYMPHIR™ has been added to the NCCN Clinical Practice Guidelines in Oncology.
📋 Key Facts
- Announcement date: September 5, 2024
- Product involved: LYMPHIR™
- Event: Inclusion in the NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology.
Citius Oncology, Inc. (formerly TenX Keane Acquisition) has filed an amendment to its 8-K to report the completion of a business combination with Citius Pharmaceuticals, Inc. ('SpinCo') via a reverse acquisition. This filing includes updated financial statements and pro forma information reflecting the combined entity.
🚩 Red Flags
- The filing is an 'Amendment No. 1' to a previous 8-K, indicating the need to provide previously missing or updated financial data following a complex merger structure.
- Complexity of reverse acquisition accounting can often lead to future restatements if integration or valuation issues arise.
📋 Key Facts
- Completed business combination on August 12, 2024.
- The transaction was structured as a 'reverse acquisition' where TenX Keane Acquisition is now Citius Oncology, Inc.
- Fiscal year end changed from December 31 to September 30, effective August 14, 2024.
- Historical financial statements of the SPAC (TenX) have been replaced with historical financial statements of SpinCo (Citius Pharmaceuticals).
- Included unaudited financial statements for the nine months ended June 30, 2024, and 2023.
Citius Oncology, Inc. (formerly TenX Keane Acquisition) completed a business combination with Citius Pharmaceuticals, Inc., resulting in the company becoming a controlled entity owned 92.6% by Citius Pharma. The transaction involved domestication from the Cayman Islands to Delaware and significant issuance of common stock for advisory fees and debt conversion.
🚩 Red Flags
- Extremely high concentration of ownership: 92.6% controlled by Citius Pharma.
- Significant dilution for original SPAC public shareholders (reduced to ~1.3%).
- The company is a 'controlled company', allowing it to bypass certain Nasdaq corporate governance standards.
- Waiver of closing conditions regarding the transfer of LYMPHIR trademark and FDA BLA/IND ownership rights (delayed by 60 days).
- Promissory note dependency: Repayment of $3.8M depends on securing a new $10M financing.
📋 Key Facts
- Business combination completed on August 12, 2024.
- Citius Pharma owns approximately 92.6% of the outstanding Company Common Stock, making it a 'controlled company'.
- TenX (the SPAC) former public shareholders own only ~1.3% of the post-closing equity.
- The transaction involved the conversion of TenX ordinary shares into Delaware common stock on a 1:1 basis.
- Citius Pharma received 65,627,262 shares as part of the merger consideration.
- Financial advisory fees were paid in stock to Maxim Group (1,872,738 shares) and Newbridge Securities (50,000 shares).
- The company issued a $3,800,111 unsecured promissory note to Citius Pharma, repayable upon a minimum financing of $10 million.
TenX Keane Acquisition (the SPAC) successfully held an extraordinary general meeting where shareholders approved a business combination with Citius Oncology, Inc. The merger includes the domestication of the company from the Cayman Islands to Delaware and the adoption of a new omnibus stock incentive plan.
🚩 Red Flags
- The merger involves a significant dilution via the new Incentive Award Plan (approx. 19.8% of fully-diluted shares).
- Implementation of a classified/staggered board can reduce shareholder ability to influence board composition in the short term.
📋 Key Facts
- Shareholders approved the Business Combination Proposal (Proposal No. 1) with significant affirmative votes.
- The company will undergo domestication from the Cayman Islands to Delaware, changing its name to 'Citius Oncology, Inc.'
- An Omnibus Stock Incentive Plan was approved, providing for up to 15,000,000 shares (approx. 19.8% of fully-diluted common stock) for compensation.
- The Board will be established as a three-class staggered board (Class I, II, and III terms).
- Shareholders approved changes to the authorized capital stock: from 150M ordinary shares to 100M common shares and 10M preferred shares.
TenX Keane Acquisition (a SPAC) has extended its deadline to complete a business combination with Citius Pharmaceuticals, Inc. by one month through August 18, 2024. This extension was facilitated by a $66,667 deposit into the company's trust account via an unsecured promissory note from Citius Pharma.
🚩 Red Flags
- Repeated use of short-term extensions suggests difficulty in meeting the original business combination timeline.
- The reliance on monthly $66,667 deposits to maintain the SPAC's existence indicates a ticking clock for the merger completion.
📋 Key Facts
- The deadline to consummate the business combination has been extended from July 18, 2024, to August 18, 2024.
- Citius Pharmaceuticals, Inc. deposited $66,667 into the Company's trust account to fund this extension.
- The deposit was structured as an unsecured promissory note issued by the Company to Citius Pharma with no interest.
- This marks the fourth successful one-month extension (following extensions in April, May, and June 2024).
- The company has a maximum of seven possible one-month extensions available from its sponsor.
TenX Keane Acquisition (a SPAC) has extended its deadline to complete a business combination with Citius Pharmaceuticals, Inc. by one month through July 18, 2024. This extension was achieved via a $66,667 deposit into the company's trust account by Citius Pharma.
🚩 Red Flags
- Repeated reliance on monthly extensions to complete a business combination suggests delays in the merger process.
- SPAC structure: The company is currently in a 'search/extension' phase, which carries inherent risk of liquidation if no merger is finalized by the final expiration date.
📋 Key Facts
- The deadline to consummate the business combination has been extended from June 18, 2024, to July 18, 2024.
- Citius Pharmaceuticals, Inc. deposited $66,667 into the company's trust account to fund this extension.
- The deposit is evidenced by an unsecured promissory note issued by the Company to Citius Pharma for $66,667.
- This marks the third successful extension (following extensions on April 26 and May 17, 2024).
- The company has a maximum of seven such one-month extensions available via this mechanism.
TenX Keane Acquisition (a SPAC) reported the completion of share redemptions following its January 2024 shareholder meeting. The company processed approximately $25 million in total redemptions, including a recent 'top-up' payment to align with an adjusted redemption price.
🚩 Red Flags
- Significant capital outflow from the trust account due to high redemption volume (typical for SPACs that fail to complete a business combination or face heavy opposition).
- Discrepancy in initial vs. adjusted redemption price calculation requiring 'top-up' payments.
📋 Key Facts
- Redeeming Shareholders exercised rights for 2,287,923 ordinary shares.
- Initial aggregate redemption amount was approximately $24.9 million based on a $10.90 per share price.
- An adjusted redemption price of $11.02 per share was determined based on the corrected calculation date (January 12, 2024).
- Additional 'top-up' payments of $268,645 were made on May 31, 2024, to cover the price difference.
- Redemptions resulted in a significant reduction of funds within the Company’s trust account.
TenX Keane Acquisition (a SPAC) has extended its deadline to complete a business combination with Citius Pharmaceuticals, Inc. by one month through June 18, 2024. This was achieved via a $66,667 deposit into the company's trust account by Citius Pharma.
🚩 Red Flags
- SPAC extension: The company is utilizing its ability to extend deadlines, indicating a delay in completing the planned merger with Citius Pharmaceuticals.
- Reliance on Sponsor/Designee deposits to maintain existence and timeline.
📋 Key Facts
- The Company extended its timeline to complete a business combination from May 18, 2024, to June 18, 2024.
- Citius Pharmaceuticals, Inc. deposited $66,667 into the company's trust account as part of the extension requirement.
- The deposit was evidenced by an unsecured promissory note issued by the Company to Citius Pharma for $66,667.
- The Note bears no interest and is repayable in full per the terms of the Merger Agreement.
TenX Keane Acquisition has extended its deadline to complete a business combination with Citius Pharmaceuticals, Inc. by one month via a sponsor contribution. The extension moves the target completion date from April 18, 2024, to May 18, 2024.
🚩 Red Flags
- SPAC extension mechanism: The company is relying on sponsor deposits to delay a business combination deadline, which can indicate difficulty in closing the original deal structure.
- Short-term window: The current extension only provides one additional month (until May 18, 2024), indicating high urgency for the merger completion.
📋 Key Facts
- The Company has until April 18, 2024, to consummate its business combination under original terms.
- The Sponsor (10XYZ Holdings LP) deposited $66,667 into the trust account on April 26, 2024, to fund a one-month extension.
- The extension period now runs from April 18, 2024, to May 18, 2024.
- The contribution is evidenced by an unsecured, non-interest-bearing promissory note issued to Citius Pharma in the amount of $66,667.
TenX Keane Acquisition (a SPAC) successfully held a shareholder meeting to approve an extension of its deadline to complete a business combination. This resulted in significant share redemptions and the issuance of a $200,000 promissory note to the Sponsor's designee.
🚩 Red Flags
- Significant capital outflow: ~$24.9 million was removed from the Trust Account due to redemptions.
- SPAC extension activity often indicates difficulty in finalizing a merger or finding favorable terms.
- The company is operating under an extended timeline, increasing the risk of liquidation if no deal is reached by April 18, 2024.
📋 Key Facts
- Shareholders approved the 'Extension Amendment Proposal', extending the liquidation date to April 18, 2024.
- The company can seek up to eight total extensions (one 3-month extension and seven 1-month extensions).
- 2,287,923 ordinary shares were redeemed at approximately $10.90 per share, totaling ~$24.9 million in redemptions.
- 6,653,077 ordinary shares remain outstanding after redemptions.
- Citius Pharma (Sponsor's designee) deposited $200,000 into the Trust Account and received a $200,000 interest-free promissory note from the Company.
TenX Keane Acquisition (a SPAC) is seeking shareholder approval to extend its deadline for completing a business combination. If approved, the Sponsor will provide additional loans to the company's trust account to fund these extensions.
🚩 Red Flags
- SPAC extension request indicates failure to find a target within the original timeframe.
- Potential for significant dilution or capital depletion through repeated extensions if a deal is not reached.
📋 Key Facts
- The Company seeks to amend its Articles of Association to extend the business combination deadline.
- Extension structure: One 3-month extension (to April 18, 2024) and up to seven 1-month extensions (through November 18, 2024).
- Sponsor Contribution for 3-month extension: Lesser of $200,000 or $0.10 per non-redeemed public share.
- Sponsor Contribution for subsequent monthly extensions: Lesser of $66,667 or $0.03 per non-redeemed public share.
- Contributions are interest-free loans from the Sponsor (10XYZ Holdings LP) to be repaid upon business combination consummation.
- If no business combination is completed by the final extended deadline, the company will liquidate and dissolve.